Astrana Health (NASDAQ:ASTH) Releases Quarterly Earnings Results, Misses Estimates By $0.46 EPS

Astrana Health (NASDAQ:ASTH) released its earnings results on Thursday. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.46), Zacks reports. Astrana Health had a net margin of 1.04% and a return on equity of 3.43%. The business had revenue of $956.05 million during the quarter, compared to analyst estimates of $952.83 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. The business’s revenue for the quarter was up 99.7% compared to the same quarter last year. Astrana Health updated its FY 2025 guidance to EPS.

Astrana Health Stock Down 23.5%

NASDAQ ASTH traded down $7.83 during trading on Friday, reaching $25.53. The company’s stock had a trading volume of 1,200,236 shares, compared to its average volume of 347,454. The business has a 50-day moving average price of $30.44 and a 200-day moving average price of $27.91. Astrana Health has a 1-year low of $21.20 and a 1-year high of $57.42. The stock has a market capitalization of $1.43 billion, a PE ratio of 50.06, a PEG ratio of 0.90 and a beta of 0.80. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.52.

Analyst Upgrades and Downgrades

ASTH has been the subject of several analyst reports. Zacks Research upgraded shares of Astrana Health from a “strong sell” rating to a “hold” rating in a research note on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Astrana Health in a research note on Wednesday, October 8th. Finally, BTIG Research dropped their price target on shares of Astrana Health from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Hedge Funds Weigh In On Astrana Health

Institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in Astrana Health by 31.4% during the second quarter. JPMorgan Chase & Co. now owns 92,201 shares of the company’s stock valued at $2,294,000 after acquiring an additional 22,030 shares during the period. Balyasny Asset Management L.P. increased its holdings in Astrana Health by 5.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 72,960 shares of the company’s stock valued at $1,815,000 after buying an additional 4,051 shares during the period. Intech Investment Management LLC raised its stake in shares of Astrana Health by 5.8% in the 1st quarter. Intech Investment Management LLC now owns 44,586 shares of the company’s stock valued at $1,383,000 after buying an additional 2,462 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Astrana Health by 46.3% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,710 shares of the company’s stock valued at $938,000 after acquiring an additional 11,942 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Astrana Health during the 1st quarter valued at about $933,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.